WELLESLEY, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY), today announced that Robert L. Bratzler, Ph.D., President & Chief Executive Officer, will be presenting a corporate update at the upcoming Lazard Capital Markets Fourth Annual Healthcare Conference at 10:00am ET on November 27th, 2007 at the New York Palace Hotel.

Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the 'Investor Events' page in the Investor Center section of the Coley website for two weeks until December 11th, 2007.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, autoimmune diseases, allergy and asthma disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government.

The company recently announced that it has entered into an agreement to be acquired by Pfizer Inc through a cash tender offer at a price of $8.00 per share. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.

SOURCE Coley Pharmaceutical Group